IAS Statin Publication|
The International Atherosclerosis Society is very pleased to announce an exciting new and informative Newsletter for its membership: The IAS Statin Newsletter. The IAS will begin this month providing curated update on all publications involving statins as identified in PubMed.
For the Issues, click here
last updated: June 16, 2017
To access some of the content on athero.org
you must be a registered user and you must log on.
You can use the interface on the right side of this page to either log on or to register.
| From the IAS President's Desk |
IAS SEVERE FH PANEL
IAS Consensus Statement “Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel”
The International Atherosclerosis Society (IAS) is proud to announce the publication on the definition of severe FH and the implications for clinical management in The Lancet Diabetes and Endocrinology. The IAS Severe FH Panel, made of 25 internationally renowned experts and chaired by Dr. Raul Santos, worked with the objective of characterizing the severe FH phenotype and made recommendations on how to stratify CVD risk and to whom to prescribe the novel lipid lowering treatments. These recommendations will contribute to improved daily clinical practice and better management of FH patients.
To download the full text, which is open access, please link to and register at http://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)30041-9/fulltext (Published online May 27, 2016). For more information about The Lancet, please visit The Lancet Homepage at www.thelancet.com.
Other FH activities
Improving management through genetic testing for Familial Hypercholesterolaemia (FH)
This e-learning has been developed for healthcare professionals with an interest in FH and genetic testing by a panel of world renowned experts in this area, Pr. Carrie and Pr. Bruckert from France, and Dr. Ballantyne and Dr. Eng in the USA and is approved by the International Atherosclerosis Society (IAS).
On completion of this e-learning you will have a better understanding of:
You can view the e-learning at http://www.cor2ed.com
- Key aspects of genetic testing in Familial Hypercholesterolaemia (FH)
- How and why to use genetic testing
- How to interpret results
- How to use cascade screening to identify related individuals at risk
NEWS FROM THE DYSLIPIDEMIA and FH CLINICS in IRAQ
After the establishment by Dr. Mutaz Al-Sabah of the first dyslipidemia and FH clinic in Iraq, a research, diagnostic and therapeutic center at the Al-Diwaniyah teaching hospital, which will ultimately separate the FH clinic in the future as an independent center dealing with familial lipid disorders, IAS is pleased to inform our readers that a second Lipid Clinic opened recently in Al-Sulaimaniya city, 400 km to the northeast of Baghdad, thanks to the impressive efforts of Dr Mutaz Al-Sabah. This clinic, supported by the collaboration with the local health authority in the Shorsh teaching hospital. This clinic will offer unique health services to patients with lipid disorders, the clinic will stands for health, research and diagnostic center which ultimately separate into a FH and dyslipidemia center after one year of work.
This represents another success story deriving from the educational activities of the IAS and OSLA in the MENA Region.
Link to the photos of the Openings
We would love to hear from our member societies about other such exciting and important successes in the field throughout the world and look forward to hearing from you.
The SAFEHEART Registry
Risk factors for atherosclerotic cardiovascular disease (ASCVD) are variable among patients with Familial Hypercholesterolaemia (FH). SAFEHEART is a multicentre, nationwide, long-term prospective contemporary cohort study of a molecularly defined FH population with or without previous ASCVD. A robust risk prediction equation (SAFEHEART-RE) has been developed using this unique cohort that shows that the risk of incident ASCVD may be estimated in FH patients using clinical and laboratory parameters including age, gender, history of ASCVD, blood pressure, body mass index, smoking, and plasma LDL-C and lipoprotein (a) levels. The Harrell's C index for this model was 0.85.
You can view it here
This information will allow more accurate ASCVD risk prediction in FH and will potentially increase the efficiency of care and use of newer lipid lowering therapies. The SAFEHEART-RE is an accurate tool to implement these predictors in daily clinical practice.
| IAS - OSLA Collaboration in the MENA Region |
The International Atherosclerosis Society (IAS) and the Oman Society of Lipid and Atherosclerosis (OSLA) are happy to make available to our readers some important documents related to the
3rd IAS – OSLA Course on Lipid Metabolism and Cardiovascular Risk which was held in Muscat, Oman (February 25-27, 2017) and co-chaired by Profs. Yuji Matsuzawa and Philip Barter of the International Atherosclerosis Society and Dr. Khalid Al-Rasadi, President of the Oman Society of Lipid and Atherosclerosis.
The 4th IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk will be held February, 2018.
To view all highlights, please click here
| Meeting and Educational Activity Highlights |
The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission:|
Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, OSLA - Oman Society of Lipids and Atherosclerosis, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd.,Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College
This site is optimised for a min. 1024 x 768 pixels resolution
The International Atherosclerosis Society (IAS), incorporated in 1979, promotes, at an international level, the advancement of science, research and teaching in the field of atherosclerosis and related diseases.
|IAS Newsletter Editors & Website Editorial Board|
Scott M. Grundy, MD, PhD
Dallas, TX, USA
Houston, TX, USA
Commentary & Newsletter Editor
(Dallas, TX, USA)